•  
  •  
 

Abstract

Background: Uterine carcinosarcoma (UCS) is a rare, highly aggressive malignancy characterized by biphasic epithelial and mesenchymal components. Tumors with heterologous sarcomatous differentiation, such as rhabdomyosarcoma, demonstrate particularly aggressive behavior, with high rates of recurrence, extrauterine spread, and poor overall prognosis. Due to its rarity, optimal management strategies remain incompletely defined.

Case Presentation: We present the case of a 70-year-old postmenopausal woman who presented with heavy daily vaginal bleeding, uterine cramping, abdominal pain, and a large protruding cervical mass on examination. Endometrial biopsy revealed carcinosarcoma with heterologous rhabdomyosarcomatous differentiation. Histopathologic evaluation demonstrated a biphasic tumor composed of high-grade adenocarcinoma and sarcomatous components with prominent rhabdomyosarcoma confirmed by desmin and MYOD1 co-expression. Imaging showed no evidence of distant metastatic disease.

Management and Outcomes: The patient underwent robotic-assisted total laparoscopic hysterectomy with bilateral salpingo-oophorectomy and sentinel lymph node mapping and biopsy. Final pathology revealed deep myometrial invasion (83%), focal cervical stromal involvement, lymphovascular space invasion, and negative lymph nodes, corresponding to FIGO Stage IIC disease (2023 classification). Immunohistochemistry demonstrated diffuse p53 overexpression and a high Ki-67 proliferation index. Postoperatively, the patient recovered without complications and reported resolution of vaginal bleeding and improvement in symptoms. Adjuvant therapy with paclitaxel, carboplatin, and vaginal cuff brachytherapy was recommended.

Conclusion: This case highlights the aggressive nature of uterine carcinosarcoma with heterologous rhabdomyosarcomatous differentiation and underscores the importance of early endometrial biopsy, comprehensive surgical staging, and multidisciplinary oncologic management. Continued reporting of such cases is essential to refine treatment strategies, improve prognostic understanding, and guide the development of standardized management guidelines for this rare malignancy.

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.